Payment overview · 2025
General Payments
$1,768.75
59 reported records · 14 companies
Healthcare provider profile · identity verified
William George Grubb, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BRUNSWICK, GA · NPI 1093721532
Verified facts
What the public records show
CMS Open Payments records show William George Grubb, MD received $1,768.75 in general payments during 2025 across 59 reported records.
Ardelyx, Inc. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Krystexxa.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $344.32 | 19.5% | 5 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $326.40 | 18.4% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $239.61 | 13.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.56 | 10.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.23 | 8.8% | 8 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $137.84 | 7.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $92.40 | 5.2% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.06 | 4.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.55 | 3.0% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $43.24 | 2.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.35 | 1.9% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.89 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.22 | 1.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $20.08 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,687.93 | 54 |
| Education | $80.82 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $292.15 | 6 | 2025 |
Source payment records
|
|||||
| XPHOZAH 30 MG Normalized: xphozah 30 mg |
Drug | Ardelyx, Inc. | $246.05 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $188.39 | 6 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $167.45 | 8 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $141.65 | 6 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $137.84 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $98.27 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.40 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $78.35 | 4 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $73.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.55 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $47.01 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $31.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| TAFINLAR Normalized: tafinlar |
Drug | Novartis Pharmaceuticals Corporation | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 328 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 188 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
328 | 70 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 112 |
| Losartan Potassium | Losartan Potassium | 517 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 129 |
| Farxiga | Dapagliflozin Propanediol | 328 | 70 |
| Allopurinol | Allopurinol | 253 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 44 |
| Ezetimibe | Ezetimibe | 222 | 54 |
| Metformin Hcl | Metformin Hcl | 205 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 53 |
| Spironolactone | Spironolactone | 202 | 55 |
| Jardiance | Empagliflozin | 188 | 39 |
| Omeprazole | Omeprazole | 175 | 45 |
| Potassium Chloride | Potassium Chloride | 165 | 37 |
| Ozempic | Semaglutide | 164 | 23 |
| Trazodone Hcl | Trazodone Hcl | 163 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 32 |
| Gabapentin | Gabapentin | 147 | 38 |
| Furosemide | Furosemide | 146 | 41 |
| Carvedilol | Carvedilol | 143 | 35 |
| Eliquis | Apixaban | 143 | 27 |
| Tramadol Hcl | Tramadol Hcl | 142 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 33 |
| Lisinopril | Lisinopril | 112 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 21 |
| Simvastatin | Simvastatin | 103 | 25 |
| Prednisone | Prednisone | 96 | 32 |
| Torsemide | Torsemide | 93 | 30 |
| Chlorthalidone | Chlorthalidone | 89 | 27 |
| Benazepril Hcl | Benazepril Hcl | 87 | 20 |
| Montelukast Sodium | Montelukast Sodium | 87 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Temazepam | Temazepam | 69 | 14 |
| Lorazepam | Lorazepam | 64 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 45 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 11 |
| Lactulose | Lactulose | 59 | 18 |
| Famotidine | Famotidine | 58 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 19 |
| Clonidine Hcl | Clonidine Hcl | 55 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 13 |
| Alendronate Sodium | Alendronate Sodium | 54 | 13 |
| Azithromycin | Azithromycin | 52 | 41 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 20 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 11 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Valsartan | Valsartan | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Calcium Acetate | Calcium Acetate | 34 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 14 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Eplerenone | Eplerenone | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 14 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Krystexxa | Pegloticase | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,768.75 · 59 records | Ardelyx, Inc. | ACTHAR, EVENITY, Empaveli, FARXIGA, Fabhalta, Filspari, GATTEX, IBSRELA, JARDIANCE, JYNARQUE, KEVEYIS, KRYSTEXXA, Kerendia, REPATHA, TAFINLAR, TARPEYO, TAVNEOS, VOYXACT, Vanrafia, XPHOZAH 30 MG, Yorvipath | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error